Allianz Asset Management
YMAB

Allianz Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Allianz Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-32,085
Closed -$485K – 2158
2022
Q2 		$485K Buy
32,085
+3,350
+12% +$39.1K ﹤0.01% 1900
2022
Q1 		$341K Sell
28,735
-1,019
-3% -$10.5K ﹤0.01% 2201
2021
Q4 		$482K Sell
29,754
-7,600
-20% -$162K ﹤0.01% 2211
2021
Q3 		$1.07M Buy
37,354
+83
+0.2% +$2.62K ﹤0.01% 1906
2021
Q2 		$1.26M Buy
37,271
+11
+0% +$353 ﹤0.01% 1651
2021
Q1 		$1.13M Sell
37,260
-179
-0.5% -$7.34K ﹤0.01% 1600
2020
Q4 		$1.85M Sell
37,439
-18,942
-34% -$876K ﹤0.01% 1337
2020
Q3 		$2.16M Sell
56,381
-1,511
-3% -$60.1K ﹤0.01% 1243
2020
Q2 		$2.5M Sell
57,892
-3,936
-6% -$149K ﹤0.01% 1519
2020
Q1 		$1.61M Buy
+61,828
New +$1.8M ﹤0.01% 1603

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Allianz Asset Management's YMAB Position: Q3 2022 in Review

Allianz Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2022, closing a stake of 32,085 shares — an estimated $485K sold.

Allianz Asset Management first reported a position in YMAB in Q1 2020 and held it in 10 quarters. The position peaked at $2.5M in Q2 2020. 100 funds tracked by Wall St. Rank hold YMAB as of Q3 2022.

  • Allianz Asset Management reported no remaining Y-mAbs Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 32,085 Y-mAbs Therapeutics shares in Q3 2022, an estimated $485K.
  • Allianz Asset Management first reported a position in Y-mAbs Therapeutics in Q1 2020 and held it in 10 quarters.
  • Allianz Asset Management's Y-mAbs Therapeutics position peaked at $2.5M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.